href=https://www.benzinga.com/quote/RMSG target=_blank>(NASDAQ: RMSG) lost 67.6% to $0.69 in pre-market trading. The company recently announced a 1-for-20 reverse stock split.The shares of Marvell Technology Inc (NASDAQ: MRVL) surged in pre-market trading after securing a spot in the S&P 500 index, while Real Messenger Corp (NASDAQ: RMSG) experienced a significant decline. Other gainers in pre-market trading include Dreamland Ltd (NASDAQ: TDIC), Gamehaus Holdings Inc (NASDAQ: GMHS), Nurix Therapeutics Inc (NASDAQ: NRIX), SmartKem Inc (NASDAQ: SMTK), Mountain Lake Acquisition Corp (NASDAQ: MLAC), Battalion Oil Corp (NASDAQ: BATL), Qtrex Quantum Ltd (NASDAQ: QTEX), Bone Biologics Corp (NASDAQ: BBLG), and Cullinan Therapeutics Inc (NASDAQ: CGEM).
As artificial intelligence, quantum computing, energy infrastructure, and next-generation healthcare technologies continue attracting investor attention, several emerging companies are positioning themselves at the intersection of some of the market's fastest-growing sectors. Investors are increasingly watching companies involved in AI infrastructure, power generation, renewable energy optimization, quantum connectivity, and AI-powered biotechnology.
Nes Ziona, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company") a company focused on advancing Additively Manufactured Electronics (“AME”) for quantum computing infrastructure, today announced that Mr. Tal Parnas, Chairman of the Company’s Board of Directors, and Mr. Yoav Rozanovich, the Company’s Chief Business Officer, will be in Boston, Massachusetts during Quantum.Tech World 2026 on June 25–26, 2026, to present functional AME-based monolithic connectivity components engineered for quantum computing systems.
Nes Ziona, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- QTREX Quantum Ltd. (Nasdaq: QTEX) ("QTREX" or the "Company") a company focused on advancing Additively Manufactured Electronics (“AME”) for quantum computing infrastructure, today announced that it received a purchase order from a Fortune 500 multinational company for an AME system and related materials. The customer is headquartered in the United States, and the AME system will be delivered to one of the customer’s sites outside the United States.
IGC Pharma, Inc. (NYSE: IGC) a clinical-stage biotechnology company developing AI-powered Alzheimer’s disease therapies, is gaining investor attention after reporting Q1 2026 financial results and continued progress in its ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for agitation associated with Alzheimer’s dementia.
